VIA
RCUS icon

Virtus Investment Advisers’s Arcus Biosciences RCUS Stock Holding History

Virtus Investment Advisers’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$274K Buy
12,664
+308
+2% +$6.65K 0.08% 296
2025
Q4 		$294K Buy
12,356
+187
+2% +$3.81K 0.08% 257
2025
Q3 		$165K Buy
12,169
+2,112
+21% +$22K 0.05% 361
2025
Q2 		$81.9K Buy
10,057
+485
+5% +$4.14K 0.03% 416
2025
Q1 		$75.1K Buy
+9,572
New +$111K 0.02% 451

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Virtus Investment Advisers's RCUS Position: Q1 2026 in Review

Virtus Investment Advisers increased its Arcus Biosciences (RCUS) stake by 2.5% in Q1 2026, buying an estimated $6.65K and bringing the position to 12,664 shares worth $274K. The position accounts for 0.08% of the portfolio, ranked #296.

Virtus Investment Advisers first reported a position in RCUS in Q1 2025 and has held it in 5 quarters since. The position peaked at $294K in Q4 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Virtus Investment Advisers held 12,664 shares of Arcus Biosciences worth $274K as of Q1 2026.
  • Virtus Investment Advisers bought 308 Arcus Biosciences shares in Q1 2026, an estimated $6.65K.
  • Arcus Biosciences made up 0.08% of Virtus Investment Advisers's portfolio in Q1 2026, its #296 holding.
  • Virtus Investment Advisers first reported a position in Arcus Biosciences in Q1 2025 and has held it in 5 quarters since.
  • Virtus Investment Advisers's Arcus Biosciences position peaked at $294K in Q4 2025.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Virtus Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.